Joining us right now is Dan Skellyy. He's Morgan Stanley's wealth management managing director. And Dan, thanks for coming in today.Morning, Becky. Um, a lot of talk about how this is the worst week we've seen since August 1st, but we're still talking about 1% declines or or less for the major averages. And maybe that tells you more about where the markets have been recently.People keep thinking this is time for a pulled back. There's time for a pullback. What do you think, Becky.First off, we've blown past ...

CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase ...

CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths ...

About this content About Stephen Gunnion Stephen Gunnion is a senior financial journalist and broadcaster at Proactive Investors. He has more than 25 years of experience in television, radio and print media, anchoring on a number of television channels including South Africa's Business Day TV, CNBC Africa and the South African Broadcasting Corporation, where he was the economics editor. He has also worked for Daily Maverick, Bloomberg, the Business Day newspaper and Investors' Chronicle. Read more About ...

Datavault AI Inc. (NASDAQ: DVLT) shares ripped higher in Thursday's after-hours trading after securing $150 million investment in Bitcoin (CRYPTO: BTC) to build a supercomputer. DVLT is surging to new heights today. Check the fundamentals here.‘Strategic’ Investment To Boost InfrastructureThe stock rallied over 23% in the after-hours session, building on its gains from the regular trading session. Shares of the data sciences technology firm jumped to an intraday high of $1.07, marking a 64% jump from the pr ...

RENO, Nev., Sept. 25, 2025 (GLOBE NEWSWIRE) -- GlobalTech Corporation (OTCID: GTLK) (“GlobalTech” or the “Company”), a U.S.-headquartered technology holding company specializing in artificial intelligence (AI), big data, and emerging technologies, today announces the appointment of a key addition to the Company’s management team.  Frank R. Parrish, III has been appointed president of GlobalTech. Mr. Parrish possesses more than 25 years of progressive experience in assurance and advisory roles in client serv ...

Medicenna Therapeutics (OTCPK:MDNA.F) 2025 Conference September 25, 2025 03:25 PM ET Company ParticipantsFahar Merchant - President, CEO & DirectorFahar MerchantGood day, everyone. Thank you for joining the Medisena presentation again. As you recall, Medisena is a TSX listed company, also listed on OTCQX. We are a company that's developing therapies for oncology, first and foremost, but generally immunotherapies. I did a presentation to you all in May, so this will be a quick update as to where we are since ...

Following the pullback seen over the two previous sessions, stocks saw further downside during trading on Thursday. The major averages continued to give back ground after ending Monday's trading at new record closing highs.The major averages ended the day well off their lows of the session but still firmly negative. The Nasdaq slid 113.16 points or 0.5 percent to 22,384.70, the S&P 500 declined 33.25 points or 0.5 percent to 6,604.72 and the Dow fell 173.96 points or 0.4 percent to 45,947.32.The continued ...

Cantor Fitzgerald upgraded UniQure NV (NASDAQ: QURE) to "Overweight" with a new price target of $80.UniQure's stock surged 248% after successful trial results for its Huntington's disease gene therapy.Analysts from Stifel, Leerink, and Mizuho have significantly raised their price targets for QURE, indicating strong confidence in its future performance.UniQure NV (NASDAQ: QURE) is a biotechnology company focused on developing gene therapies. It aims to provide innovative treatments for patients with severe g ...

Question-and-Answer SessionSo perhaps we could start by having you give our audience a brief overview of Entrada Therapeutics and in particular, the Endosomal Escape Vehicles technology platform.Dipal DoshiCEO & Director Yes, happy to do that. So Entrada is a clinical stage biotech company that is aiming to transform patients' lives. We have a proprietary application or technology called Endosomal Escape Vehicles that we also call EEVs. We'll use that interchangeably, which we really believe enhances the va ...